Mirador Therapeutics
Olivier Laurent is an accomplished biotechnology executive with extensive experience leading research and development efforts. Currently serving as Chief Scientific Officer at Mirador Therapeutics, Olivier has held significant leadership positions such as Chief Scientific Officer and Head of R&D at Prometheus Biosciences, where innovative approaches to treating immune-mediated diseases were developed. Previous roles include Chief Scientific Officer at Dauntless Pharmaceuticals and Intrepida Bio, along with critical positions at Pfizer, where Olivier oversaw protein science and therapeutic peptide strategies. Olivier's academic foundation includes a Ph.D. in Cell Biology from Université Joseph Fourier and a Master's in Molecular and Cellular Biology from École normale supérieure de Lyon.
This person is not in any offices
Mirador Therapeutics
Mirador is a next-generation precision medicine company focused on immunology and inflammation. The company’s Mirador360 TM precision development engine leverages the latest advances in human genetics and cutting-edge data science to rapidly advance new precision medicines for patients living with chronic immune-mediated inflammatory and fibrotic diseases. Launched in 2024, Mirador has raised over $400 million from leading life sciences investors and is based in San Diego, CA.